JP2018538241A - 乳癌におけるカゼインキナーゼ１δの治療標的化 - Google Patents

乳癌におけるカゼインキナーゼ１δの治療標的化 Download PDF

Info

Publication number
JP2018538241A
JP2018538241A JP2018519027A JP2018519027A JP2018538241A JP 2018538241 A JP2018538241 A JP 2018538241A JP 2018519027 A JP2018519027 A JP 2018519027A JP 2018519027 A JP2018519027 A JP 2018519027A JP 2018538241 A JP2018538241 A JP 2018538241A
Authority
JP
Japan
Prior art keywords
ck1δ
cancer
breast cancer
catenin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018519027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538241A5 (enExample
Inventor
ロウシュ，ウィリアム・アール
ダケット，デレク・アール
クリーブランド，ジョン・エル
ローゼンバーグ，ローラ・エイチ
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2018538241A publication Critical patent/JP2018538241A/ja
Publication of JP2018538241A5 publication Critical patent/JP2018538241A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018519027A 2015-10-13 2016-10-05 乳癌におけるカゼインキナーゼ１δの治療標的化 Pending JP2018538241A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562240689P 2015-10-13 2015-10-13
US62/240,689 2015-10-13
PCT/US2016/055436 WO2017066055A1 (en) 2015-10-13 2016-10-05 THERAPEUTIC TARGETING OF CASEIN KINASE 1δ IN BREAST CANCER

Publications (2)

Publication Number Publication Date
JP2018538241A true JP2018538241A (ja) 2018-12-27
JP2018538241A5 JP2018538241A5 (enExample) 2019-11-14

Family

ID=58517824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519027A Pending JP2018538241A (ja) 2015-10-13 2016-10-05 乳癌におけるカゼインキナーゼ１δの治療標的化

Country Status (8)

Country Link
US (2) US10603322B2 (enExample)
EP (1) EP3362452A4 (enExample)
JP (1) JP2018538241A (enExample)
CN (1) CN108431006A (enExample)
AU (1) AU2016338639A1 (enExample)
CA (1) CA3001903A1 (enExample)
HK (1) HK1259409A1 (enExample)
WO (1) WO2017066055A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200078387A1 (en) * 2016-12-16 2020-03-12 The Johns Hopkins University Chemical inhibitors against kinases to block telomere elongation in cancer
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
WO2019217421A1 (en) 2018-05-08 2019-11-14 The Scripps Research Institute Small molecule inhibitors of cdk12/cdk13
WO2020041607A1 (en) * 2018-08-22 2020-02-27 Merck Patent Gmbh Treatment of triple negative breast cancer with targeted tgf-b inhibition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150274729A1 (en) * 2012-02-29 2015-10-01 The Scripps Research Institute Wee1 degradation inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9346812B2 (en) 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150274729A1 (en) * 2012-02-29 2015-10-01 The Scripps Research Institute Wee1 degradation inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORG.MED.CHEM.LETT., vol. 23, no. 15, JPN6020033353, 2013, pages 4374 - 4380, ISSN: 0004476088 *
MOL.CANCER THER., vol. 12, no. 11, JPN6020033354, 2013, pages 269, ISSN: 0004476089 *

Also Published As

Publication number Publication date
CN108431006A (zh) 2018-08-21
EP3362452A1 (en) 2018-08-22
AU2016338639A1 (en) 2018-05-10
CA3001903A1 (en) 2017-04-20
US10603322B2 (en) 2020-03-31
HK1259409A1 (zh) 2019-11-29
US20200163972A1 (en) 2020-05-28
WO2017066055A1 (en) 2017-04-20
US20180311252A1 (en) 2018-11-01
EP3362452A4 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
Rosenberg et al. Therapeutic targeting of casein kinase 1δ in breast cancer
Konishi et al. γ-Secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers
Kim et al. Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer
Zhang et al. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells
Hao et al. Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis
Li et al. NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3
Zhang et al. Demethylzeylasteral inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axis
Zhou et al. miR-675-5p enhances tumorigenesis and metastasis of esophageal squamous cell carcinoma by targeting REPS2
T. Sankpal et al. Expression of specificity protein transcription factors in pancreatic cancer and their association in prognosis and therapy
Jang et al. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation
Wang et al. CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation
Zheng et al. miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway
US20200163972A1 (en) Therapeutic Targeting of Casein Kinase 1 Delta in Breast Cancer
Wu et al. CircAPLP2 regulates the proliferation and metastasis of colorectal cancer by targeting miR-101-3p to activate the Notch signalling pathway
Guo et al. Knockdown of FRAT1 expression by RNA interference inhibits human glioblastoma cell growth, migration and invasion
Ho et al. Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and activates the hypoxia signaling pathway
Han et al. Long non-coding RNA JPX promotes gastric cancer progression by regulating CXCR6 and autophagy via inhibiting miR-197
Wu et al. MicroRNA-181b blocks gensenoside Rg3-mediated tumor suppression of gallbladder carcinoma by promoting autophagy flux via CREBRF/CREB3 pathway
Han et al. TIMP3 overexpression improves the sensitivity of osteosarcoma to cisplatin by reducing IL-6 production
Xie et al. Wilms’ tumor 1-Associated protein contributes to Chemo-Resistance to cisplatin through the Wnt/β-Catenin pathway in endometrial Cancer
Zhou et al. Homeobox B4 inhibits breast cancer cell migration by directly binding to StAR‑related lipid transfer domain protein 13
Hu et al. Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis
WO2016020427A1 (en) Macc1 inhibitors and use thereof in the treatment of cancer
Zhang et al. miR-802 inhibits the aggressive behaviors of non-small cell lung cancer cells by directly targeting FGFR1
Ning et al. PCDH20 inhibits esophageal squamous cell carcinoma proliferation and migration by suppression of the mitogen-activated protein kinase 9/AKT/β-catenin pathway

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191003

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210330